Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant vs Physician's Choice in ER+/HER2- Advanced Breast Cancer
NCT04576455Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of giredestrant in breast cancer, sponsored by Roche. Started Nov 2020; status: active, not recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04576455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576455.